Loading...

Analysts Adjust Borregaard Price Target and Valuation Following Recent Updates and Ongoing Developments

Published
02 Feb 25
Updated
04 Jun 26
Views
111
04 Jun
NOK 144.60
AnalystConsensusTarget's Fair Value
NOK 183.80
21.3% undervalued intrinsic discount
Loading
1Y
-23.9%
7D
2.8%

Author's Valuation

NOK 183.821.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Last Update 04 Jun 26

Fair value Decreased 7.45%

BRG: Dividend Support And Margin Resilience Will Underpin Future Upside

The analyst fair value estimate for Borregaard has moved from NOK 198.60 to NOK 183.80 as analysts factor in updated assumptions on revenue growth, profit margins and future P/E following recent supportive research updates from Danske Bank and Kepler Cheuvreux.

Analyst Commentary

Bullish Takeaways

  • Bullish analysts highlight that recent research updates support a more constructive view on Borregaard's earnings power, which feeds directly into a higher comfort level around the updated fair value range.
  • They see the current P/E assumptions used in the fair value estimate as supported by the company's positioning in its markets, which they view as helping justify a premium to more cautious scenarios.
  • Supportive research points to confidence in Borregaard's ability to execute on its business plan, which analysts tie to a more resilient margin outlook in their models.
  • The updated work from bullish analysts is framed as reducing uncertainty around revenue and profit assumptions, which in turn tightens valuation ranges and underpins their positive stance on the stock.

Bearish Takeaways

  • Bearish analysts focus on the fact that, even with supportive research, the fair value estimate has been revised to NOK 183.80, which they see as highlighting ongoing caution around revenue growth assumptions.
  • They flag that projected profit margins in the models still carry execution risk, especially if cost pressures or weaker demand scenarios play out more harshly than currently factored in.
  • Some cautious views question whether the implied P/E in the updated valuation leaves enough margin of safety if earnings come in below current expectations.
  • There is also concern that, despite positive commentary, any unexpected operational setbacks or weaker pricing power could put pressure on the fair value estimate and lead to further model adjustments.

What's in the News

  • Borregaard and other major shareholders have provided additional liquidity support to Alginor after challenges with raw material supply, delayed product development and commercialisation, and cost overruns in Alginor's demonstration plant investment, source: Borregaard ASA: Alginor faces a challenging financial situation.
  • Alginor has frozen investment in its demonstration plant and introduced temporary layoffs to maintain operations, with Borregaard participating in the funding support during this period, source: Borregaard ASA: Alginor faces a challenging financial situation.
  • Borregaard has commenced a share repurchase program from May 11, 2026, under an AGM mandate that authorizes buybacks of up to 9,994,413 shares (10% of outstanding share capital) at prices between NOK 1 and NOK 400 per share. The program is valid until the 2027 AGM or no later than June 30, 2027.
  • Within this broader mandate, Borregaard announced a specific buyback of 300,000 shares, to be carried out between May 11, 2026 and June 18, 2026. The repurchased shares are intended for employee incentive programs and potential amortization.
  • Borregaard has issued 2026 sales volume guidance, indicating expected full year volumes of around 340,000 tonnes for BioSolutions, 155,000 to 160,000 tonnes for BioMaterials compared with 146,000 tonnes in 2025, and higher volumes for Fine Chemical intermediates compared with 2025. Fine Chemicals bioethanol prices are expected to be largely in line with 2025 levels.

Valuation Changes

  • Fair Value: changed from NOK 198.60 to NOK 183.80, a reduction that reflects updated modelling assumptions.
  • Discount Rate: changed from 7.00% to 7.02%, a very small upward move in the required return used in the valuation work.
  • Revenue Growth: changed from 5.42% to 4.82%, indicating slightly more cautious expectations for future top line expansion in NOK terms.
  • Net Profit Margin: changed from 13.48% to 15.73%, a higher margin assumption that points to a stronger earnings mix on each NOK of revenue in the updated model.
  • Future P/E: changed from 20.0x to 16.2x, a lower multiple applied to forward earnings, which reduces the valuation sensitivity to higher earnings scenarios.
0 viewsusers have viewed this narrative update

Key Takeaways

  • Strong demand for green products and high-value specialties is expected to boost sales and margins, driving revenue growth for Borregaard.
  • Operational improvements and currency hedging could stabilize revenue and enhance financial resilience despite trade and currency challenges.
  • Trade tensions and increased expenses could affect Borregaard's revenue and margins, while reliance on agriculture exposes it to sector-specific risks.

Catalysts

About Borregaard
    Engages in the development, production, and marketing of specialized biochemicals and biomaterials in Norway, rest of Europe, Asia, the United States, and internationally.
What are the underlying business or industry changes driving this perspective?
  • Strong sales in the agriculture segment, driven by the increasing demand for green and biocontrol products, are expected to positively impact revenue growth and EBITDA margins.
  • The favorable product mix in BioSolutions, particularly with high-value specialty products, is anticipated to boost overall earnings and contribute to higher net margins.
  • Tariffs and trade dynamics, although presenting some uncertainty, might have less impact on Borregaard due to its highly specialized products and diverse market presence, thereby potentially stabilizing revenue despite global trade fluctuations.
  • Continuous investment and focus on operational improvements, such as the electrification of biopolymer spray dryers to reduce energy costs, are likely to enhance net margins over time.
  • Ongoing currency hedging strategies and anticipated positive currency effects are expected to have a favorable impact on EBITDA and earnings, providing financial resilience amidst currency volatility.
Borregaard Earnings and Revenue Growth

Borregaard Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Borregaard's revenue will grow by 4.8% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 7.2% today to 15.7% in 3 years time.
  • Analysts expect earnings to reach NOK 1.4 billion (and earnings per share of NOK 11.4) by about June 2029, up from NOK 551.0 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as NOK830.3 million.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 16.3x on those 2029 earnings, down from 25.2x today. This future PE is lower than the current PE for the GB Chemicals industry at 25.2x.
  • Analysts expect the number of shares outstanding to grow by 0.22% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.02%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • The introduction of a 10% tariff on imports from Norway into the U.S. could impact Borregaard's revenues from their U.S. sales, as 10% of their sales last year came from Norway to the U.S. The lower volume of exports due to these tariffs might have a negative effect on revenue.
  • Increased supply of advanced bioethanol in Europe, based on agricultural waste, is expected to lead to significantly lower sales prices for Borregaard's bioethanol, which could decrease revenue and impact net margins in the Fine Chemicals segment.
  • Higher wood and logistical costs have increased expenses for Borregaard, which could limit the company's ability to increase net margins and impact overall profitability.
  • Potential negative effects on global GDP growth from tariffs and trade tensions could ultimately reduce demand for Borregaard's products, affecting revenue growth across its segments.
  • The strong current reliance on the agricultural sector for BioSolutions' revenues might expose Borregaard to risks associated with any downturn in agriculture or shifts in customer demand, potentially impacting revenues and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of NOK183.8 for Borregaard based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of NOK220.0, and the most bearish reporting a price target of just NOK160.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be NOK8.8 billion, earnings will come to NOK1.4 billion, and it would be trading on a PE ratio of 16.3x, assuming you use a discount rate of 7.0%.
  • Given the current share price of NOK139.2, the analyst price target of NOK183.8 is 24.3% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Borregaard?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives